Differential associations of NFL and GFAP with neuropsychiatric symptoms by amyloid status across the Alzheimer’s disease continuum
BackgroundNeuropsychiatric symptoms (NPS) are key clinical manifestations across the Alzheimer’s disease (AD) continuum and predict worse clinical outcomes, yet their biological correlates remain incompletely understood. It remains unclear whether biomarkers of neuroaxonal injury and astrocytic acti...
| Published in: | Frontiers in Neurology |
|---|---|
| Main Authors: | Jiaonan Wu, Haitang Jiang, Rui Wang, Xinyi Lv, Fang Tang, Xianliang Chai, Yao Zhu, Zhaozhao Cheng, Yan Wu, Qiqiang Tang |
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2026-04-01
|
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2026.1782816/full |
Similar Items
Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia
by: Assunta Ingannato, et al.
Published: (2024-04-01)
by: Assunta Ingannato, et al.
Published: (2024-04-01)
The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.
by: Sara Samadzadeh, et al.
Published: (2025-03-01)
by: Sara Samadzadeh, et al.
Published: (2025-03-01)
Serum GFAP, NfL, and tau concentrations are associated with worse neurobehavioral functioning following mild, moderate, and severe TBI: a cross-sectional multiple-cohort study
by: Katie A. Edwards, et al.
Published: (2024-01-01)
by: Katie A. Edwards, et al.
Published: (2024-01-01)
Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
by: Johannes Heinrich Alexander Piel, et al.
Published: (2024-03-01)
by: Johannes Heinrich Alexander Piel, et al.
Published: (2024-03-01)
Plasma NfL and GFAP as Candidate Biomarkers of Disease Activity in NMOSD and MOGAD
by: Jarmila Szilasiová, et al.
Published: (2025-10-01)
by: Jarmila Szilasiová, et al.
Published: (2025-10-01)
Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
by: Soheil Mohammadi, et al.
Published: (2025-07-01)
by: Soheil Mohammadi, et al.
Published: (2025-07-01)
Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury
by: Katerina Vlasakova, et al.
Published: (2024-01-01)
by: Katerina Vlasakova, et al.
Published: (2024-01-01)
Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: a mini review
by: Rachel E. Rodin, et al.
Published: (2024-05-01)
by: Rachel E. Rodin, et al.
Published: (2024-05-01)
Diagnostic value of fluid‐based non‐amyloid biomarkers for Alzheimer's disease and related dementias in a clinic‐based cohort from South Asia
by: Faheem Arshad, et al.
Published: (2025-04-01)
by: Faheem Arshad, et al.
Published: (2025-04-01)
Evaluating plasma biomarkers NfL, GFAP, GDF15, and FGF21 as indicators of disease severity in Charcot–Marie Tooth patients
by: Dace Pretkalnina, et al.
Published: (2025-01-01)
by: Dace Pretkalnina, et al.
Published: (2025-01-01)
Primitive Neuroectodermal Tumor Prognosis
by: J Gordon Millichap
Published: (1996-05-01)
by: J Gordon Millichap
Published: (1996-05-01)
Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint
by: Deborah O. T. Alawode, et al.
Published: (2022-04-01)
by: Deborah O. T. Alawode, et al.
Published: (2022-04-01)
GFAP-Negative Subcutaneous Sacrococcygeal Extraspinal Ependymoma
by: Kazuya Goto, et al.
Published: (2021-06-01)
by: Kazuya Goto, et al.
Published: (2021-06-01)
Systematic assessment of plasma biomarkers in spinocerebellar ataxia
by: Xue-Ning Shen, et al.
Published: (2023-06-01)
by: Xue-Ning Shen, et al.
Published: (2023-06-01)
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
by: Ka Young Kim, et al.
Published: (2023-05-01)
by: Ka Young Kim, et al.
Published: (2023-05-01)
A case of glial fibrillary acidotic protein (GFAP) meningoencephalitis with rheumatoid arthritis
by: Mehri Salari, et al.
Published: (2023-03-01)
by: Mehri Salari, et al.
Published: (2023-03-01)
Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology
by: Anita L. Sunde, et al.
Published: (2023-04-01)
by: Anita L. Sunde, et al.
Published: (2023-04-01)
Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease
by: Arda C. Cetindag, et al.
Published: (2026-05-01)
by: Arda C. Cetindag, et al.
Published: (2026-05-01)
Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort
by: Bin Jiao, et al.
Published: (2025-04-01)
by: Bin Jiao, et al.
Published: (2025-04-01)
Case report: Headache as the sole neurological symptom in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy
by: Eslam Shosha, et al.
Published: (2024-04-01)
by: Eslam Shosha, et al.
Published: (2024-04-01)
Uncommon manifestations of a rare disease: a case of autoimmune GFAP astrocytopathy
by: Hong Di, et al.
Published: (2021-01-01)
by: Hong Di, et al.
Published: (2021-01-01)
Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease
by: Madeline Ally, et al.
Published: (2023-10-01)
by: Madeline Ally, et al.
Published: (2023-10-01)
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases
by: Wongu Youn, et al.
Published: (2025-05-01)
by: Wongu Youn, et al.
Published: (2025-05-01)
Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42
by: Camilla Lauridsen, et al.
Published: (2017-06-01)
by: Camilla Lauridsen, et al.
Published: (2017-06-01)
Soluble curcumin prevents cadmium cytotoxicity in primary rat astrocytes by improving a lack of GFAP and glucose-6-phosphate-dehydrogenase
by: V. S. Nedzvetsky, et al.
Published: (2018-11-01)
by: V. S. Nedzvetsky, et al.
Published: (2018-11-01)
Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy
by: Shugang Cao, et al.
Published: (2023-05-01)
by: Shugang Cao, et al.
Published: (2023-05-01)
Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy
by: Akio Kimura, et al.
Published: (2022-03-01)
by: Akio Kimura, et al.
Published: (2022-03-01)
Physical activity and blood‐based biomarkers of neurodegeneration in community dwelling Australians from ISLAND (Island Study Linking Ageing and Neurodegenerative Disease)
by: Eddy Roccati, et al.
Published: (2025-07-01)
by: Eddy Roccati, et al.
Published: (2025-07-01)
Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-12-01)
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-12-01)
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-11-01)
by: Fernando Rodríguez-Jorge, et al.
Published: (2024-11-01)
Emerging biomarkers for improving pregnancy planning in multiple sclerosis
by: Juan Pablo Cuello, et al.
Published: (2024-02-01)
by: Juan Pablo Cuello, et al.
Published: (2024-02-01)
Oncological challenges in GFAP-positive anaplastic meningioma: a case report and literature review
by: Minh Huu Nhat Le, et al.
Published: (2025-01-01)
by: Minh Huu Nhat Le, et al.
Published: (2025-01-01)
Diagnostic performance of plasma GFAP in preclinical stages of Alzheimer’s disease using the Lumipulse platform
by: Andrea Valera-Barrero, et al.
Published: (2026-03-01)
by: Andrea Valera-Barrero, et al.
Published: (2026-03-01)
Relapsing Autoimmune GFAP Astrocytopathy: Case Report
by: Ekaterina O. Chekanova, et al.
Published: (2023-12-01)
by: Ekaterina O. Chekanova, et al.
Published: (2023-12-01)
Whether Serum Glial Fibrillary Acidic Protein (GFAP) Can Be Used as a Diagnostic Biomarker in Patients With Glioblastoma?
by: Charandeep Singh Gandhoke, et al.
Published: (2020-01-01)
by: Charandeep Singh Gandhoke, et al.
Published: (2020-01-01)
Distribution of GFAP in Squamata: Extended Immunonegative Areas, Astrocytes, High Diversity, and Their Bearing on Evolution
by: Dávid Lõrincz, et al.
Published: (2020-08-01)
by: Dávid Lõrincz, et al.
Published: (2020-08-01)
Encephalitis with Antibodies Against Glial Fibrillary Acidic Protein (GFAP) After Allogeneic Hematopoietic Stem Cell Transplantation: A Rare Case Report and Literature Review
by: Liu J, et al.
Published: (2024-08-01)
by: Liu J, et al.
Published: (2024-08-01)
Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: To Identify Its Diagnosis, Management and Prognosis (GFAP-AID) Registry: Study Protocol for an Ambispective, Multicenter Registry in China
by: Yang J, et al.
Published: (2022-06-01)
by: Yang J, et al.
Published: (2022-06-01)
Central autonomic network dysfunction and plasma Alzheimer’s disease biomarkers in older adults
by: Trevor Lohman, et al.
Published: (2024-06-01)
by: Trevor Lohman, et al.
Published: (2024-06-01)
Immunohistochemical analysis of α-SMA and GFAP expression in liver stellate cells
by: Tomanović Nada, et al.
Published: (2006-01-01)
by: Tomanović Nada, et al.
Published: (2006-01-01)
Similar Items
-
Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia
by: Assunta Ingannato, et al.
Published: (2024-04-01) -
The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications.
by: Sara Samadzadeh, et al.
Published: (2025-03-01) -
Serum GFAP, NfL, and tau concentrations are associated with worse neurobehavioral functioning following mild, moderate, and severe TBI: a cross-sectional multiple-cohort study
by: Katie A. Edwards, et al.
Published: (2024-01-01) -
Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis
by: Johannes Heinrich Alexander Piel, et al.
Published: (2024-03-01) -
Plasma NfL and GFAP as Candidate Biomarkers of Disease Activity in NMOSD and MOGAD
by: Jarmila Szilasiová, et al.
Published: (2025-10-01)
